RYTM · Rhythm Pharmaceuticals, Inc. · Metrics
$95.22
-0.50 (-0.52%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$6.79B
Shares
68.85M
Volume · Sep 30
737.18K
Avg daily vol (3M)
650.29K
RYTM metrics
67 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$95.22
Market cap
$6.79B
Price action
20 metricsPrice change (1W)
-3.6%
Price change (30D)
-9.8%
Price change (3M)
-13.8%
Price change (6M)
+10.0%
Price change (YTD)
-10.6%
Price change (1Y)
-4.9%
Trailing year
Price change (5Y)
+625.6%
52-week high
$117.62
52-week low
$75.82
Change from 52-week high
-18.6%
Change from 52-week low
+26.2%
Annualized volatility
46.5%
Annualized volatility (3M)
38.1%
Beta
1.0
RSI (14D)
34.0
Price vs SMA 50
-9.7%
Price vs SMA 200
-3.5%
Avg volume (3M)
654,249
Relative volume
1.2
Average dollar volume
$69.86M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
68.85M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
27.4×
reciprocal yield 3.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
28.3×
reciprocal yield 3.5%
P / book
66.0
reciprocal yield 1.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
32.4×
reciprocal yield 3.1%
EV / revenue historical average (5Y)
75.6×
reciprocal yield 1.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-04
Profitability
9 metricsGross margin
89.0%
Operating margin
-83.6%
Trailing 12 months
Net margin
-85.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$200.63M
Net income (TTM)
−$205.35M
Trailing 12 months
Diluted EPS (TTM)
$-3.11
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+46.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$239.92M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+7.7%
Year over year · more shares
Revenue CAGR (3Y)
+100.2%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-199.4%
Return on assets
-47.0%
Debt / equity
1.0
Current ratio
3.5
EBITDA (TTM)
−$153.13M
Free cash flow (TTM)
—
Quick ratio
3.2
Interest coverage
-10.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$224.79M
Latest balance sheet
Cash & equivalents
$65.61M
Total assets
$437.27M
Total debt
$106.10M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$105.35M
Capital expenditures (TTM)
—
R&D (TTM)
$173.21M
SG&A (TTM)
$240.95M
Stock compensation (TTM)
$87.23M
R&D / revenue
72.2%
Stock compensation / revenue
36.4%
Ownership (13F)
3 metrics13F filers
307
13F filer change QoQ
+20
Institutional ownership
112.5%
Short interest
3 metricsShort interest
14.9%
Latest settlement · 20.1 days to cover
Days to cover
20.1d
Short-squeeze score
63 / 100
Insider activity
2 metricsNet insider buying (90D)
−$28.80M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—